Autres langues HighTide Therapeutics, Inc.

Actions

2511

KYG4568L1023

Recherche biotechnologique et médicale

Temps Différé Hong Kong S.E. 08:01:55 21/09/2026			Varia. 5j.	Varia. 1 janv.
3,405 ^HKD	+3,18%		+2,25%	+15,42%

31/08	HighTide Therapeutics, Inc. publie ses résultats pour le semestre clos le 30 juin 2026	CI
02/07	HighTide Therapeutics et son PDG resilient un contrat de pret suite aux reserves de la Bourse	MT

Autres langues

31/08	HighTide Therapeutics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026
02/07	HighTide Therapeutics, CEO Terminate Loan Contract on Bourse's Concerns
04/05	HighTide Therapeutics, Inc. Announces Board and Committee Changes, Effective May 4, 2026
28/04	HighTide Therapeutics Agrees to Lend HK$15 Million to CEO
27/04	Hightide Therapeutics enters loan agreement up to HK$15 million
05/04	Moving Beyond the 'Blockbuster' Legacy to Reshape Kidney Disease Treatment Through a Dual-Mechanism Approach: Dialogue with HighTide Therapeutics' CMO Dr. Filip Surmont
27/03	HighTide Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
10/03	HighTide Therapeutics Gets China Acceptance for Type 2 Diabetes Mellitus Drug
10/03	HighTide Therapeutics says NMPA China accepts new drug application for HTD1801
10/03	HighTide Therapeutics, Inc. Announces Acceptance of New Drug Application for HTD1801 by China?s National Medical Products Administration
05/02	HighTide Therapeutics Completes Phase IIb Trial of Metabolic Dysfunction-Associated Steatohepatitis Drug
05/02	HighTide Therapeutics, Inc. Announces Completion of Phase IIb Clinical Study of HTD1801 for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
02/02	HighTide Therapeutics Appoints Chief Medical Officer
02/02	HighTide Therapeutics, Inc. Appoints Dr. Filip Surmont As Chief Medical Officer
10/12	HighTide Therapeutics Presents Renal Data for HTD1801, Reinforcing Its Potential as a Foundational CKM Therapy
02/12	HighTide Therapeutics Drug Found Better at Treating Type 2 Diabetes in Trial
02/12	HighTide Therapeutics, Inc. Announces Positive Topline Results from its Phase III Harmony Trial
07/11	HighTide Therapeutics Presents the Evidence of Kidney Benefit with HTD1801
31/10/25	HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
31/10/25	HighTide Therapeutics - HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
31/10/25	HighTide Therapeutics Reports Positive 52-Week Phase 3 Results for Diabetes Drug
31/10/25	HighTide Therapeutics, Inc. Announces Positive 52-Week Efficacy and Safety Results from the Open-Label Extension Phase III Trials
22/09/25	HighTide Therapeutics, Inc.(SEHK:2511) added to S&P Global BMI Index
17/09/25	EASD 2025 \| HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes
26/08/25	HighTide Therapeutics Narrows H1 Loss; Shares Rise 7%